Dyne Therapeutics, Inc. (DYN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum.
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for... Read more
Sell if holding. Engine safety override at $15.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Dyne Therapeutics, Inc.
Latest news
- Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystr — benzinga May 20, 2026 positive
- Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33 — benzinga May 15, 2026 positive
- Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24 — benzinga May 13, 2026 positive
- Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate — benzinga May 11, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinez-rostudirsen (DMD exon 51)10-K Item 1: 'We plan to submit a biologics license application, or BLA, to the U.S. Food and Drug Administration, or FDA, for U.S. Accelerated Approval of z-rostudirsen for DMD patients who have mutations amenable to exon 51 skipping in the second quarter of 2026'
- HIGHpipelinez-basivarsen (DM1)10-K Item 1: 'We plan to submit a BLA to the FDA for U.S. Accelerated Approval of z-basivarsen for DM1 patients early in the third quarter of 2027.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $15.39. Score 4.8/10, moderate confidence.
Take-profit target: $34.37 (+115.8% upside). Prior stop was $15.39. Stop-loss: $15.39.
Concentration risk — Pipeline: z-rostudirsen (DMD exon 51); Concentration risk — Pipeline: z-basivarsen (DM1); Quality below floor (1.6 < 4.0).
Dyne Therapeutics, Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover DYN with a consensus score of 4.2/5. Average price target: $38.
What does Dyne Therapeutics, Inc. do?Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases,...
Dyne Therapeutics is a clinical-stage biotech developing FORCE platform-based therapeutics for neuromuscular diseases, with lead assets z-rostudirsen (DYNE-251) for DMD exon 51 skipping and z-basivarsen (DYNE-101) for DM1. BLA submission for z-rostudirsen planned Q2 2026 for U.S. Accelerated Approval; Phase 3 confirmatory trials for both programs planned in 2026.